{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T14:31:09Z","timestamp":1770993069311,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,8,22]],"date-time":"2009-08-22T00:00:00Z","timestamp":1250899200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1007\/s00432-009-0662-9","type":"journal-article","created":{"date-parts":[[2009,8,21]],"date-time":"2009-08-21T04:29:53Z","timestamp":1250828993000},"page":"363-370","source":"Crossref","is-referenced-by-count":18,"title":["Disease-specific risk for an osteonecrosis of the jaw under bisphosphonate therapy"],"prefix":"10.1007","volume":"136","author":[{"given":"Tatjana I.","family":"Jung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Falk","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd","family":"Glaeske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dieter","family":"Felsenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,8,22]]},"reference":[{"key":"662_CR1","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/annonc\/mdn788","volume":"20","author":"J Ayllon","year":"2009","unstructured":"Ayllon J, Launay-Vacher V, Medioni J, Cros C, Spano JP, Oudard S (2009) Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile? Ann Oncol 20:600\u2013601","journal-title":"Ann Oncol"},{"key":"662_CR2","first-page":"E336","volume":"12","author":"J Bagan","year":"2007","unstructured":"Bagan J, Blade J, Cozar JM, Constela M, Garcia Sanz R, Gomez Veiga F, Lahuerta JJ, Lluch A, Massuti B, Morote J, San Miguel JF, Solsona E (2007) Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Med Oral Patol Oral Cir Bucal 12:E336\u2013E340","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"662_CR3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1517\/13543784.14.1.45","volume":"14","author":"A Bamias","year":"2005","unstructured":"Bamias A, Dimopoulos MA (2005) Thalidomide and immunomodulatory drugs in the treatment of cancer. Expert Opin Investig Drugs 14:45\u201355","journal-title":"Expert Opin Investig Drugs"},{"key":"662_CR4","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","volume":"23","author":"A Bamias","year":"2005","unstructured":"Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580\u20138587","journal-title":"J Clin Oncol"},{"key":"662_CR5","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.oraloncology.2007.11.012","volume":"44","author":"T Boonyapakorn","year":"2008","unstructured":"Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G (2008) Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 44:857\u2013869","journal-title":"Oral Oncol"},{"key":"662_CR6","first-page":"223","volume":"5","author":"A Brzozowska","year":"2003","unstructured":"Brzozowska A, Mazurkiewicz M, Mazurkiewicz T, Grzybowska-Szatkowska L (2003) The impact of bisphosphonate therapy on the survival time of patients undergoing radiotherapy for bone metastases. Ortop Traumatol Rehabil 5:223\u2013226","journal-title":"Ortop Traumatol Rehabil"},{"key":"662_CR7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3816\/CLM.2008.n.013","volume":"8","author":"AM Cafro","year":"2008","unstructured":"Cafro AM (2008) Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid. Clin Lymphoma Myeloma 8:111\u2013116","journal-title":"Clin Lymphoma Myeloma"},{"key":"662_CR8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.14219\/jada.archive.2008.0016","volume":"139","author":"VM Cartsos","year":"2008","unstructured":"Cartsos VM, Zhu S, Zavras AI (2008) Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. J Am Dent Assoc 139:23\u201330","journal-title":"J Am Dent Assoc"},{"key":"662_CR9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","volume":"76","author":"C Christodoulou","year":"2009","unstructured":"Christodoulou C, Pervena A, Klouvas G, Galani E, Falagas ME, Tsakalos G, Visvikis A, Nikolakopoulou A, Acholos V, Karapanagiotidis G, Batziou E, Skarlos DV (2009) Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 76:209\u2013211","journal-title":"Oncology"},{"key":"662_CR10","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/sj.leu.2404682","volume":"21","author":"A Corso","year":"2007","unstructured":"Corso A, Varettoni M, Zappasodi P, Klersy C, Mangiacavalli S, Pica G, Lazzarino M (2007) A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 21:1545\u20131548","journal-title":"Leukemia"},{"key":"662_CR11","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00228-001-0411-8","volume":"57","author":"S Cremers","year":"2002","unstructured":"Cremers S, Sparidans R, den HJ, Hamdy N, Vermeij P, Papapoulos S (2002) A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis. Eur J Clin Pharmacol 57:883\u2013890","journal-title":"Eur J Clin Pharmacol"},{"key":"662_CR12","unstructured":"Dassinger M, Dootz H, Grohmann I, Hoffmann K, Kuhlmann A, L\u00f6we M, Pfleger A, Schiel N, Selz C, Sieprath S, Sy K (2008) Rote liste. In: Rote Liste Service GmbH Frankfurt\/Main. http:\/\/www.rote-liste.de\/ . Accessed 6 August 2008"},{"key":"662_CR13","first-page":"968","volume":"91","author":"MA Dimopoulos","year":"2006","unstructured":"Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, Bamia C, Terpos E, Tsionos K, Bamias A (2006) Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 91:968\u2013971","journal-title":"Haematologica"},{"key":"662_CR14","unstructured":"Felsenberg D, Hoffmeister B, Amling M, Mundlos S, Seibel M, Fratzl P (2006) Kiefernekrosen nach hoch dosierter Bisphosphonattherapie. Deutsches Aerzteblatt 103:3078\u20133081"},{"key":"662_CR15","first-page":"6538","volume":"62","author":"P Fournier","year":"2002","unstructured":"Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, Clezardin P (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62:6538\u20136544","journal-title":"Cancer Res"},{"key":"662_CR16","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.tripleo.2006.12.004","volume":"104","author":"R Gutta","year":"2007","unstructured":"Gutta R, Louis PJ (2007) Bisphosphonates and osteonecrosis of the jaws: science and rationale. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 104:186\u2013193","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"662_CR17","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","volume":"23","author":"AO Hoff","year":"2008","unstructured":"Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23:826\u2013836","journal-title":"J Bone Miner Res"},{"key":"662_CR18","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/pds.1634","volume":"17","author":"F Hoffmann","year":"2008","unstructured":"Hoffmann F, Jung TI, Felsenberg D, Glaeske G (2008) Pattern of intravenous bisphosphonate use in outpatient care in Germany. Pharmacoepidemiol Drug Saf 17:896\u2013903","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"662_CR19","first-page":"S113","volume":"22","author":"TI Jung","year":"2007","unstructured":"Jung TI, von der Gablentz J, Hoffmeister B, Mundlos S, Fratzl P, Amling M, Seibel MJ, Felsenberg D (2007) Osteonecrosis of the jaw under bisphosphonate therapy: patient profile and risk assessment. J Bone Miner Res 22:S113","journal-title":"J Bone Miner Res"},{"key":"662_CR20","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","volume":"22","author":"S Khosla","year":"2007","unstructured":"Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479\u20131491","journal-title":"J Bone Miner Res"},{"key":"662_CR21","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1182\/blood.V93.1.300","volume":"93","author":"MQ Lacy","year":"1999","unstructured":"Lacy MQ, Donovan KA, Heimbach JK, Ahmann GJ, Lust JA (1999) Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 93:300\u2013305","journal-title":"Blood"},{"key":"662_CR22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","volume":"18","author":"JH Lin","year":"1996","unstructured":"Lin JH (1996) Bisphosphonates: a review of their pharmacokinetic properties. Bone 18:75\u201385","journal-title":"Bone"},{"key":"662_CR23","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115\u20131117","journal-title":"J Oral Maxillofac Surg"},{"key":"662_CR24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jebdp.2008.12.014","volume":"9","author":"CA Migliorati","year":"2009","unstructured":"Migliorati CA (2009) Low incidence of osteonecrosis of the jaw in postmenopausal women with osteoporosis taking zoledronic acid once yearly. J Evid Based Dent Pract 9:13\u201315","journal-title":"J Evid Based Dent Pract"},{"key":"662_CR25","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.14219\/jada.archive.2005.0108","volume":"136","author":"CA Migliorati","year":"2005","unstructured":"Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB (2005) Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc 136:1658\u20131668","journal-title":"J Am Dent Assoc"},{"key":"662_CR26","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1200\/JCO.2005.01.7756","volume":"24","author":"MD Mignogna","year":"2006","unstructured":"Mignogna MD, Fedele S, Lo Russo L, Ciccarelli R, Lo Muzio L (2006) Case 2. Osteonecrosis of the jaws associated with bisphosphonate therapy. J Clin Oncol 24:1475\u20131477","journal-title":"J Clin Oncol"},{"key":"662_CR27","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2141.2007.06705.x","volume":"138","author":"G Pratt","year":"2007","unstructured":"Pratt G, Goodyear O, Moss P (2007) Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 138:563\u2013579","journal-title":"Br J Haematol"},{"key":"662_CR28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bone.2008.09.012","volume":"44","author":"IR Reid","year":"2009","unstructured":"Reid IR (2009) Osteonecrosis of the jaw: who gets it, and why? Bone 44:4\u201310","journal-title":"Bone"},{"key":"662_CR29","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","volume":"88","author":"MJ Rogers","year":"2000","unstructured":"Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88:2961\u20132978","journal-title":"Cancer"},{"key":"662_CR30","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","volume":"62","author":"SL Ruggiero","year":"2004","unstructured":"Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527\u2013534","journal-title":"J Oral Maxillofac Surg"},{"key":"662_CR31","first-page":"2893","volume":"9","author":"D Santini","year":"2003","unstructured":"Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, Gavasci M, Rocci L, Tirindelli MC, Altomare V, Tocchini M, Bonsignori M, Tonini G (2003) Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 9:2893\u20132897","journal-title":"Clin Cancer Res"},{"key":"662_CR32","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jclinepi.2006.07.002","volume":"59","author":"DA Southern","year":"2006","unstructured":"Southern DA, Faris PD, Brant R, Galbraith PD, Norris CM, Knudtson ML, Ghali WA (2006) Kaplan\u2013Meier methods yielded misleading results in competing risk scenarios. J Clin Epidemiol 59:1110\u20131114","journal-title":"J Clin Epidemiol"},{"key":"662_CR33","doi-asserted-by":"crossref","unstructured":"Terpos E, Sezer O, Croucher PI, Garc\u00eda-Sanz R, Boccadoro M, San Miguel J, Ashcroft J, Blad\u00e9 J, Cavo M, Delforge M, Dimopoulos M-A, Facon T, Macro M, Waage A, Sonneveld P (2009) The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol. Advance Accessed 22 May 2009","DOI":"10.1093\/annonc\/mdn796"},{"key":"662_CR34","doi-asserted-by":"crossref","unstructured":"Walter C, Al-Nawas B, Grotz KA, Thomas C, Thuroff JW, Zinser V, Gamm H, Beck J, Wagner W (2008) Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 54:1066\u20131072","DOI":"10.1016\/j.eururo.2008.06.070"},{"key":"662_CR35","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.joms.2007.03.006","volume":"65","author":"EP Wang","year":"2007","unstructured":"Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ (2007) Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 65:1328\u20131331","journal-title":"J Oral Maxillofac Surg"},{"key":"662_CR36","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/jnci\/djm025","volume":"99","author":"GS Wilkinson","year":"2007","unstructured":"Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS (2007) Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst 99:1016\u20131024","journal-title":"J Natl Cancer Inst"},{"key":"662_CR37","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.joms.2006.02.011","volume":"64","author":"AI Zavras","year":"2006","unstructured":"Zavras AI, Zhu S (2006) Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis? J Oral Maxillofac Surg 64:917\u2013923","journal-title":"J Oral Maxillofac Surg"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-009-0662-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-009-0662-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-009-0662-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T16:29:05Z","timestamp":1590078545000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-009-0662-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,22]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["662"],"URL":"https:\/\/doi.org\/10.1007\/s00432-009-0662-9","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,22]]}}}